Figure 1.

Differences in circulating cytokine concentrations between patients with disease control and patients with progressive disease during FOLFIRINOX treatment. (A) Concentrations of pro-inflammatory (eotaxin, IL-1β, and IL-18) and anti-inflammatory cytokines (IL-7, IL-1RA, sIL-2R) in serum of individual patients with disease control (n=64) and patients with progressive disease (n=19) before start of FOLFIRINOX (V1) and after one cycle of FOLFIRINOX (V2) and the median concentration over time for the two response groups. Median concentrations before or after one cycle did not show statistical significant differences between the two groups. (B) Percentage increase of serum IL-18 concentrations after one cycle of FOLFIRINOX in patients with disease control and progressive disease. **P < 0.01, calculated with Mann-Whitney U test.